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Background and purpose — Soft-tissue sarcoma (STS) is rare, 
with challenging individualized treatment, so diagnostics and 
treatment should be centralized. Historical controls are some-
times used for investigation of whether new diagnostic or thera-
peutic tools affect patient outcome. However, as yet unknown fac-
tors may affect the outcome. We investigated prognostic factors 
and prognosis in 2 nationwide cohorts of patients diagnosed with 
a local STS during the periods 1998–2001 and 2005–2010, with 
special interest in fi nding factors lying behind possible improve-
ment of prognosis.
Patients and methods — 2 cohorts of patients with STS of the 
extremities or trunk diagnosed during the periods 1998–2001 and 
2005–2010 were retrieved from the nationwide Finnish Cancer 
Registry. Detailed information was gathered from patient fi les.
Results — Compared to fi rst cohort, a larger proportion of 
patients with inadequate surgery in the second cohort received 
radiation therapy, and both the local control rate and the sar-
coma-specifi c survival rate improved in the second cohort. For 
sarcoma-specifi c survival, cohort (HR = 0.6, 95% CI: 0.5–0.9), 
age, depth, grade, and margin were signifi cant factors in multi-
variate analysis. For local control, cohort (HR = 0.6, 95% CI: 0.5–
0.9), age, and margin were signifi cant in multivariate analysis.
Interpretation — Known prognostic factors including type of 
treatment did not entirely explain the secular trend of continuous 
improvement in prognosis in STS. This illustrates the danger of 
using historical controls for investigation of whether new diagnos-
tic or therapeutic tools have an effect on patient outcome.
■
Treatment of soft-tissue sarcoma (STS) is highly demanding 
and it should—by consensus—be centralized in large centers 
with adequate experience. Primary treatment of localized STS 
has for a long time been surgery with clear margins, and this 
has been increasingly combined with (neo-) adjuvant radiation 
therapy. The role of adjuvant chemotherapy remains unclear, 
and the estimated benefi t, if any, remains small (Pervaiz et al. 
2008). The main treatment principles have remained the same 
for several decades (Leyvraz et al. 2005, ESMO 2014).
The prognosis of STS has gradually improved during the last 
decades despite the fact that there has been no major break-
through in the principles of treatment of the disease. In Fin-
land, the 5-year survival has stayed the same (67–66%) in men 
but it increased in women from 58% in 1999–2003 to 68% in 
2009–2013, and the trend has been similar in other Nordic 
contries (Bray et al. 2010, Engholm et al. 2016). The Scandi-
navian Sarcoma Group (SSG) introduced a treatment program 
for soft-tissue sarcoma (SSG V) in 1986, and the protocol 
was widely adopted in Finland. We have reported the benefi t 
of fi rm adherence to treatment protocol at the largest tertiary 
sarcoma referral center in Finland—Helsinki University Hos-
pital (Wiklund et al. 1996, Sampo et al. 2008). In a Swed-
ish SSG study, metastasis-free survival improved between 2 
cohorts at Karolinska Hospital from 57% (in patients treated 
1986–1989) to 75% (in patients treated 1997–2002). Better 
referral policy for smaller lesions at least partly explained the 
improvement, but a question was raised as to whether other 
underlying reasons might also have been responsible for the 
better outcome (Bauer et al. 2004).
The main aim of the present study was to investigate prog-
nostic factors and prognosis in 2 nationwide patient cohorts 
diagnosed with a local STS during the periods 1998–2001 and 
2005–2010. We were especially interested in fi nding factors 
responsible for possibly improved prognosis.
Acta Orthopaedica 2017; 88 (1): 116–120 117
Material and methods
Data for patients diagnosed with a local STS of the extremity 
or trunk wall in Finland during 1998–2001 and 2005–2010 
were retrieved from the nationwide population-based Finnish 
Cancer Registry. The Finnish Cancer Registry covers more 
than 99% of the solid tumors diagnosed in Finland (Teppo et 
al. 1994, Forman et al. 2014).
Detailed clinical data were collected from the patient fi les. 
Patients with dermatofi brosarcoma protuberans, grade-I lipo-
sarcoma/atypical lipoma, and cutaneous leiomyosarcoma were 
excluded from the analysis. 2 patients were excluded because 
of missing fi les. We also excluded patients who received treat-
ment with palliative intention, leaving 215 patients during the 
period 1998–2001 and 359 patients during 2005–2010 for 
analysis, all of whom had primary local STS of the extremi-
ties or trunk.
Helsinki University Hospital (HUH) has weekly multimo-
dality STS meetings and has long been the main center for 
STS treatment. Consultations from other university hospitals 
(Tampere, Turku, Oulu, Kuopio) are also referred to Helsinki. 
HUH treated 177 (105) patients and the other 4 university 
hospitals treated 28–69 (8-28) patients each. (The numbers 
in parentheses refer to patients who were treated during the 
period 1998–2001). Only 1–3 patients were treated at each 
of 14 (17) other institutions (district hospitals and primary 
healthcare units). Altogether, defi nite surgeries were per-
formed at 19 institutions during 2005–2010 and at 23 institu-
tions during 1998–2001.
Defi nitions of surgical margins were adapted from the 
Enneking classifi cation (Enneking et al. 1981). In Helsinki, 
the surgical margin was defi ned as wide if the smallest micro-
scopic margin in the fi xed specimen measured at least 2.5 
cm. In some university hospitals in Finland, the cutoff point 
is 1 cm and the margin was defi ned accordingly. A smaller 
margin was accepted as being wide, however, if it consisted 
of an anatomical barrier with no involvement (such as fascia). 
If the requirements for a wide margin were not fulfi lled, the 
margin was classifi ed as marginal (margins negative but less 
than 2.5 cm (1 cm) wide) or as intralesional (microscopic or 
macroscopic tumor left). The mean length of follow-up of the 
survivors was 5.2 (2.2–9.4) years for the 2005–2010 cohort 
and 7.0 (0.6–12) years for the 1998–2001 cohort.
Statistics
Possible differences in tumor, patient, and treatment charac-
teristics in the 2 cohorts were assessed with the χ2 test and 
Fisher’s exact test. Local recurrence-free rates, metastasis-free 
rates, and sarcoma-specifi c survival rates were calculated with 
the Kaplan-Meier method. If the univariate test showed a sig-
nifi cant association (p ≤ 0.05) between a descriptive variable 
and the survival rate, this variable was included in a Cox pro-
portional hazards model for multivariate analysis. IBM SPSS 
Statistics version 22 was used for all analyses.
Ethics
The study was approved by the Joint Ethics Commit-
tee of Helsinki University Hospital (270/13/03/00/2001, 
5.8.2014) and by the National Institute for Health and Welfare 
(THL/919/5.05.00/2014, 29.12.2014).
Results
The only statistically signifi cant difference between the 2 
cohorts was a shift in histological diagnosis (Table 1). Undiffer-
entiated pleomorphic sarcoma was the commonest subtype in 
both cohorts. More patients had preoperative histology needle 
biopsy in the second cohort, although as many as one quarter of 
patients in the second cohort were operated without any previ-
ous biopsy (Table 2). Of the patients referred to STS centers in 
the 5 university hospitals for treatment of primary tumors, the 
percentage of untouched tumors increased from 45% to 54%.
Table 1. Patient and tumor characteristics in patients of the 2 cohorts
 
 Cohort Cohort 
 2005–2010 1998–2001 c
 n = 359 n = 215
Histology  
 UPS 123   89
 Liposarcoma   59   41
 Leiomyosarcoma   57   36
 MPNST   14     1
 Synovial sarcoma   19   22
 Fibrosarcoma   15     8
 Myxofi brosarcoma   20     2
 Sarcoma otherwise specifi ed     9     8
 Sarcoma not otherwise specifi ed   43     8
Grade  
 Low   73   56
 High 286 158
Size (cm), mean (SD) a 8.0 (5.4) 7.7 (5.6)
Site  
 Lower extremity 185 109
 Trunk wall 119   62
 Upper extremity   55   44
Depth  
 Superfi cial b 122   66
 Deep 237 149
Postirradition sarcoma  
 Yes   12     3
 No 347 212
Age (years), mean (SD) 62 (18) 62 (17)
Sex  
 Male 192 132
 Female 167   83
MPNST = malignant peripheral nervous sheath tumor. 
UPS = undifferentiated pleomorphic sarcoma. 
a Largest diameter in fi xed specimen. 
b Subcutaneous tumor with or without cutaneous extension. 
c Of the characteristics only distributions of histologic subtypes  
differed signifi cantly (p < 0.001), chi squared test or Fischers exact 
test.
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Compared to the fi rst cohort, more patients in the 2005–
2010 cohort had only 1 defi nite operation, more patients had a 
wide defi nite margin, more patients with an inadequate margin 
received radiation therapy, and more patients received chemo-
therapy (Table 2).
Surgery and complications
Of the 359 patients, 251 (70%) did not require any reconstruc-
tion after resection of the tumor (skin transplants excluded). 
54 patients (15%) required pedicled fl ap reconstruction, 38 
(11%) required microvascular fl ap reconstruction, 6 patients 
required vascular reconstruction, and 10 patients required 
reconstruction with surgical mesh. The complication rate 
was not associated with the number of primary surgeries. The 
30-day complication rate after defi nite surgery was 26%. When 
only major complications were considered (treatment-related 
death, hematoma evacuation/infection requiring further sur-
gery, infection requiring intravenous antibiotics, re-anastomo-
sis, revision requiring pedicled or microvascular fl ap), the rate 
was 17%. 2 treatment-related deaths were recorded: 1 patient 
developed a major stroke after surgery and 1 patient developed 
systemic infection and empyema after reconstruction with 
pedicled latissimus dorsi fl ap and surgical mesh.
Radiation therapy
Of the patients with an inadequate defi nite margin (intrale-
sional or marginal), 78% in the second cohort received adju-
vant radiation therapy as compared to 66% in the fi rst cohort.
Survival
Both local recurrence-free survival (5-year LRFS; 86% vs. 
77%) and sarcoma-specifi c survival (5-year survival; 79% 
vs. 68%) improved in the second cohort (Figures 1 and 2). 
Metastasis-free survival also improved (5-year MFS; 73% vs. 
67%; p = 0.05).
Table 2. Characteristics of diagnostics and treatment in the 2 cohorts
  
 Cohort Cohort 
 2005–2010 1998–2001
Variable n = 359 n = 215 p-value d
Preoperative diagnosis   <0.001
 None 94 96 
 Cytology 7 8 
 Core needle biopsy 236 99 
 Open biopsy 22 12 
Number of operations   0.007
 1 251 125 
 2 105 84 
 3 3 6 
First margin a   0.2
 Intralesional 88 67 
 Marginal 20 23 
Defi nite margin   <0.001
 Intralesional 25 44 
 Marginal 217 112 
 Wide 117 58 
Surgery extent b   0.7
 Amputation 26 15 
 Limb-sparing surgery 214 138 
Radiation therapy c   0.01
 Yes 188 103 
 No 54 53 
Chemotherapy   0.01
 Yes  72 26 
 No 287 189 
a For 108 and 90 patients having > 1 surgery for the primary tumor. 
b 240 and 153 tumors of the extremities. 
c for 242 and 156 with intralesional or marginal defi nite surgery. 
d
 χ2  test or Fisher's exact test.   
Numbers at risk
2005–2010: 359 329 284 252 206 143 48 22
1998–2001: 215 175 147 124 114 104 70 53
Figure 1. Local control plotted against time. Blue line: 2005–2010 
cohort, green line: 1998–2001 cohort (p = 0.003)
Numbers at risk
2005–2010: 359 340 303 272 225 157 56 22
1998–2001: 215 196 166 145 130 119 81 62
Figure 2. Sarcoma-specifi c survival plotted against time. Blue line: 
2005–2010 cohort, green line: 1998–2001 cohort (p = 0.005)
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Factors affecting local control and sarcoma-specifi c 
survival
In univariate analysis, second vs. fi rst cohort (HR = 0.6, 95% 
CI: 0.4–0.8), younger age, and wider margin gave better local 
control. In multivariate analysis, these factors all remained 
Table 4. Uni- and multivariate analyses on prognostic factors for metastases
   
     
 Univariate analysis Multivariate analysis 
 Relative risk 95% CI  p-value Relative risk 95% CI p-value
Cohort (former vs. latter)  0.7 0.5–1.0 0.05 0.8 0.6–1.1 0.2
Age per year  1.0 1.0–1.01 0.05
Margin category a 0.6 0.5–0.8 < 0.001 0.7 0.5–0.9 0.04
Size per cm 1.09 1.07–1.1 < 0.001 1.07 1.05–1.1 < 0.001
Radiation therapy (yes vs. no) 1.6 1.2–2.2 0.003 0.8 0.5–1.3 0.4
Sex (female vs. male) 1.5 1.1–2.1 0.01 1.5 1.1–2.1 0.04
Depth (superfi cial vs. deep) 2.4 1.6–3.6 < 0.001 1.6 1.0–2.5 0.05
Grade (low grade vs. high grade) 3.9 2.2–6.7 < 0.001 4.0 2.0–7.9 < 0.001
Site (extremity vs. trunk wall) 1.0 0.7–1.3 0.8   
Post-irradiation sarcoma (yes vs. no) 1.02 0.4–2.7 1.0   
Chemotherapy (yes vs no) 1.3 0.9–1.9 0.2   
      
a Intralesional vs. marginal vs. wide.      
Table 5. Uni- and multivariate analyses on prognostic factors for sarcoma-related death
   
     
 Univariate analysis Multivariate analysis 
 Relative risk 95% CI  p-value Relative risk 95% CI p-value
Cohort (former vs. latter)  0.6 0.4–0.8 0.005 0.6 0.5–0.9 0.005
Age per year  1.02 1.01–1.04 < 0.001 1.02 1.01–1.03 0.001
Margin category a 0.5 0.4–0.6 < 0.001 0.6 0.4–0.7 < 0.001
Size per cm 1.0 1.0–1.01 0.6
Radiation therapy (yes vs. no) 1.3 0.9–1.8 0.1
Sex (female vs. male) 1.2 0.9–1.7 0.2
Depth (superfi cial vs. deep) 2.2 1.5–3.3 < 0.001 1.8 1.2–2.8 0.003
Grade (low grade vs. high grade) 3.3 1.9–5.6 < 0.001 3.2 1.9–5.5 < 0.001
Site (extremity vs. trunk wall) 1.1 0.7–1.4 1   
Post-irradiation sarcoma (yes vs. no) 0.9 0.4–2.3 0.8   
Chemotherapy (yes vs no) 1.3 0.8–1.8 0.4   
      
a Intralesional vs. marginal vs. wide.      
Table 3. Uni- and multivariate analyses on prognostic factors for local recurrence  
 
     
 Univariate analysis Multivariate analysis 
 Relative risk 95% CI  p-value Relative risk 95% CI p-value
Cohort (former vs. latter) 0.6 0.4–0.8 0.003 0.6 0.4–0.9 0.01
Age per year  1.03 1.02–1.05 < 0.001 1.03 1.01–1.05 < 0.001
Margin category a 0.3 0.2–0.5 < 0.001 0.4 0.3–0.6 < 0.001
Size per cm 1.006 1.0–1.01 0.08   
Radiation therapy (yes vs. no) 1.2 0.8–1.2 0.4   
Sex (female vs. male) 1.3 0.8–1.9 0.3   
Depth (superfi cial vs. deep) 1.3 0.8–2.0 0.3   
Grade (low grade vs. high grade) 1.1 0.7–1.8 0.7   
Site (extremity vs. trunk wall) 1.2 0.8–1.8 0.4   
Post-irradiation sarcoma (yes vs. no) 0.5 0.2–1.5 0.2   
Chemotherapy (yes vs no) 0.8 0.5–1.5 0.5   
      
a Intralesional vs. marginal vs. wide.      
statistically signifi cant (Table 3).
For metastases-free survival, 
depth, grade, margin, sex, size, 
and radiation therapy were of 
prognostic value in univariate 
analysis. Second vs. fi rst cohort 
(HR = 0.7, 95% CI: 0.5–1.0) and 
age were of borderline signifi -
cance. Grade, margin, size, and 
sex were statistically signifi cant 
in multivariate analysis (Table 4).
For sarcoma-specifi c survival, 
second vs. fi rst cohort (HR = 0.6, 
95% CI: 0.4–0.8), age, depth, 
grade, and margin were of prog-
nostic value in univariate analy-
sis. They all remained statisti-
cally signifi cant in multivariate 
analysis (Table 5).
Discussion
5-year local recurrence-free sur-
vival improved by 9% and sar-
coma-specifi c survival by 11% 
between the 2 cohorts (1998–
2001 and 2005–2010). Finnish 
Cancer Registry data showed an 
8% improvement in overall sur-
vival during the corresponding 
decade (1999–2003 to 2009–
2013) (Engholm et al. 2016). The 
somewhat larger improvement in 
our study may be explained by 
different endpoint (cancer-spe-
cifi c as opposed to age-adjusted 
overall survival) and the fact that 
only patients treated with cura-
tive intent were included in our 
analysis. In a SEER study from 
the USA, the improvement was 
even more impressive; 5-year 
overall survival improved by 32% 
over 13 years from 1991–1996 to 
2004–2010 (Jacobs et al. 2015). 
During this period, the treatment 
modalities have been practically 
the same.
In the present study, the cohorts (1998–2001 vs. 2005–2010) 
showed independent prognostic value for local control and 
sarcoma-specifi c survival in both univariate and multivariate 
analysis. Part of the improvement in outcome might probably 
be explained by improved diagnostics and better adherence 
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to treatment recommendations, because patients had fewer 
operations for the primary tumor, had better surgical margins, 
and had more use of radiation therapy and chemotherapy in 
the second cohort. Multivariate analyses, where these factors 
were adjusted for, still showed a statistically signifi cant effect 
of the cohort on local control and disease-specifi c survival, 
indicating that these factors did not completely capture all 
the factors responsible for the improvement in outcome. In 
an SSG registry material from Karolinska Hospital, not only 
local control but also metastasis-free survival improved (57% 
vs. 75%) in soft-tissue sarcoma patients (treated in the period 
1986–1989 or in the period 1997–2002, respectively) (Bauer 
et al. 2004). Some of the improvement was due to improved 
referral policy including more patients with small and super-
fi cial tumors, but the authors speculated that this alone might 
not explain the dramatic survival benefi t. Unfortunately, sar-
coma-specifi c survival was not reported.
The retrospective setting of our study can be seen as a 
weakness, with data gathered primarily for reasons other 
than research purposes. Patients with poor physical perfor-
mance status or substantial comorbidities, with only palliative 
treatment, were excluded. Because there were few histotype 
changes at histological review in our previous study due to 
centralized pathology diagnostics (Sampo et al. 2012), no 
histological review was performed in the present study. Het-
erogenous defi nitions of wide surgical margins and different 
selection criteria for patients receiving radiation therapy may 
cause inaccuracy in the local control analysis. The strength of 
the study was the truly nationwide cohort based on the reli-
able Finnish Cancer Registry, with almost 100% completeness 
regarding solid tumors (Teppo et al. 1994, 2014).
Awareness of sarcoma treatment guidelines among physi-
cians who see patients presenting with soft-tissue masses 
remains unsatisfactory in Finland, as only 55% of patients 
were referred to an STS center untouched during the period 
2005–2010. The proportion is higher than during 1998–2001 
(41%), but it leaves room for improvement.
In summary, both local control rate and sarcoma-specifi c 
survival improved over time. Known prognostic factors or 
type of treatment did not entirely explain this improvement, 
suggesting the presence of other as yet unknown factors. Our 
fi ndings make the use of historical controls for evaluation of 
new treatment forms questionable.
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